<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013194</url>
  </required_header>
  <id_info>
    <org_study_id>IRRB/01/06</org_study_id>
    <nct_id>NCT01013194</nct_id>
  </id_info>
  <brief_title>Human Fetal Liver Cell Transplantation in Chronic Liver Failure</brief_title>
  <acronym>hFLCTx</acronym>
  <official_title>Human Fetal Liver Cell Transplantation for Treatment of Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Mediterranean Institute for Transplantation and Advanced Specialized Therapies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Mediterranean Institute for Transplantation and Advanced Specialized Therapies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The herein study consists in the transplantation of liver progenitor cells isolated from
      human fetal liver tissue with the aim of improving conventional liver therapy and broadening
      therapeutical options other than liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the major clinical problems in transplantation medicine is the discrepancy between the
      growing number of liver chronic disease patients and the lack of organs. Research and
      development of new liver failure treatments thus have a high clinical significance.
      Regenerative medicine and results recently achieved in the field of stem cell biology may
      provide a remedy to this emerging problem.

      Our project aims at developing new generation cell transplantation methodologies through an
      interdisciplinary research project created from a collaboration between ISMETT, Palermo and
      the University of Pittsburgh (UPMC-USA).

      Adult hepatocyte transplantation has been in use for several years already and has proved to
      be safe for patients and able, especially in pediatric patients, to improve liver function
      indices and delay the need for liver transplantation. Studies have been limited until now by
      the use of already differentiated hepatocytes and therefore unable to proliferate and develop
      a suitable liver mass to support a decompensated liver.

      The hypothesis of our project, supported by in vitro studies and studies on experimental
      animal models, is based on the possibility to generate an ectopic liver system in the spleen
      through the experimental use of hepatic cell progenitors obtained from human fetal liver
      tissues. Human fetal liver cell transplantation will be performed in the spleen through
      arterial injection.

      The final endpoint of the project is to develop an innovative and safe treatment for patients
      with end-stage chronic liver failure
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of treated and control patients survival at 1 year follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of Child-Pugh Score From Baseline to 1 Year Follow-up</measure>
    <time_frame>Baseline and 1 year Follow-up</time_frame>
    <description>Assessment of the efficacy of human fetal liver progenitor cell transplantation on Child-Pugh score.
The Child-Pugh (CP) classification is a scoring system used for the classification of the severity of cirrhosis. It includes three continuous variables (bilirubin, albumin and INR) and two discrete variables (ascites and encephalopathy). Each variable is scored 1-3 with 3 indicating most severe derangement. The determination of CP score may range from 5 to 15 and the final score allows to categorize patients in Child-Pugh A (5-6 points), B (7-9 points) and C (10-15 points). The highest is the score the sickest is the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Meld Score From Baseline to 1 Year Follow-up</measure>
    <time_frame>Baseline and 1 year Follow-up</time_frame>
    <description>Assessment of the efficacy of human fetal liver progenitor cell transplantation on Meld score.
The Model for End-stage Liver Disease (MELD) scoring system aims at stratifying recipients by their disease severity according to a score estimating the 3-month probability of death on the waiting list. The calculation of an individual's MELD score is based on three objective lab parameters (bilirubin, serum creatinine and prothrombin time expressed as international normalized ratio, INR) and it includes logarithmic transformations and multiplication by several factors. It ranges between 6 and 40. The highest is the score the lower is the patient's survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cirrhotic patients treated with Human Fetal Liver Cell Transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Cirrhotic patients on Standard therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Human Fetal Liver Cell Transplantation</intervention_name>
    <description>Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.
Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.
Cell infusion: between 5 and 10x10^8 cells. Number of sessions: up to 2.</description>
    <arm_group_label>Treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis (evidence of chronic liver disease, presence of ascites and/or
             esophageal varices upon superior digestive endoscopy and/or ultrasound evidence of
             portal hypertension) or histological diagnosis of liver cirrhosis with any etiology.

          -  Serious liver failure documented by a score ≥ B8 based on the Child-Pugh-Turcotte
             classification and/or MELD score ≥ 14.

          -  Informed consent to the study signed by the patient.

        Exclusion Criteria:

          -  MELD score ≥ 25

          -  Hepatocellular carcinoma (HCC)

          -  Portal vein thrombosis

          -  Serious cardiovascular or respiratory disease, or other medical condition which may
             threaten patient's life in the subsequent three months

          -  Admission to the Intensive Care Unit (ICU)

          -  Hemodynamic instability (MAP &lt; 55 mmHg)

          -  Use of vasoactive drugs (Epinephrine, Norepinephrine, Vasopressin, Dopamine,
             Terlipressine

          -  Type-1 (acute) hepatorenal syndrome

          -  Levels of serum creatinine &gt;2 mg/dl and/or creatinine clearance &lt;30-40 ml/min

          -  Sepsis, active infection or spontaneous bacterial peritonitis

          -  Active gastrointestinal bleeding or recent gastrointestinal bleeding episode (in the
             previous 4 weeks)

          -  Active alcohol abuse

          -  Severe alcoholic hepatitis

          -  Pulmonary hypertension (PAP &gt; 35 mmHg)

          -  History of neoplasia

          -  Pregnancy

          -  Non Sicilian residency

          -  HBV DNA positive

          -  HIV infection

          -  Drug addiction

          -  Age &lt; 18 years

          -  Transjugular intrahepatic portosystemic shunt (TIPS) placed in the previous month

          -  Contraindications to the procedure (e.g., related to the splenic artery: aneurysm,
             kinking, thrombosis, splenic-renal shunt; related to the spleen: large angioma).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Gridelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ISMETT-UPMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ISMETT</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <results_first_submitted>October 29, 2014</results_first_submitted>
  <results_first_submitted_qc>October 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2015</results_first_posted>
  <last_update_submitted>October 2, 2015</last_update_submitted>
  <last_update_submitted_qc>October 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver cirrhosis</keyword>
  <keyword>Fetal stem cells</keyword>
  <keyword>Stem cell transplantation</keyword>
  <keyword>Liver transplant candidate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treated Patients</title>
          <description>Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.
Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.
Cell infusion: between 5x10^8 and 10x10^8 cells. Number of sessions: up to 2.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Cirrhotic patients in waiting list for Liver Transplantation on standard therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">Consecutive patients</participants>
                <participants group_id="P2" count="16">Retrospectively contemporary matched-pair group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated Patients</title>
          <description>Patients with end-stage chronic liver disease in waiting list for liver transplantation treated with non-purified and non-selected fetal liver cells.</description>
        </group>
        <group group_id="B2">
          <title>Control Patients</title>
          <description>Patients with end-stage chronic liver disease on standard therapy in waiting list for liver transplantation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Survival</title>
        <description>Assessment of treated and control patients survival at 1 year follow-up</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
            <description>Patients with end-stage chronic liver disease in waiting list for Liver Transplantation treated with hFLCTx</description>
          </group>
          <group group_id="O2">
            <title>Control Patients</title>
            <description>Patients with end-stage chronic liver disease in waiting list for Liver Transplantation on standard therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival</title>
          <description>Assessment of treated and control patients survival at 1 year follow-up</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death/Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4340</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Child-Pugh Score From Baseline to 1 Year Follow-up</title>
        <description>Assessment of the efficacy of human fetal liver progenitor cell transplantation on Child-Pugh score.
The Child-Pugh (CP) classification is a scoring system used for the classification of the severity of cirrhosis. It includes three continuous variables (bilirubin, albumin and INR) and two discrete variables (ascites and encephalopathy). Each variable is scored 1-3 with 3 indicating most severe derangement. The determination of CP score may range from 5 to 15 and the final score allows to categorize patients in Child–Pugh A (5–6 points), B (7–9 points) and C (10–15 points). The highest is the score the sickest is the patient.</description>
        <time_frame>Baseline and 1 year Follow-up</time_frame>
        <population>Baseline Child-Pugh score vs Follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
            <description>Cirrhotic patients in waiting list for Liver Transplantation treated with non-purified and non-selected fetal liver stem cells</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Cirrhotic patients in waiting list for Liver Transplantation on standard therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Child-Pugh Score From Baseline to 1 Year Follow-up</title>
          <description>Assessment of the efficacy of human fetal liver progenitor cell transplantation on Child-Pugh score.
The Child-Pugh (CP) classification is a scoring system used for the classification of the severity of cirrhosis. It includes three continuous variables (bilirubin, albumin and INR) and two discrete variables (ascites and encephalopathy). Each variable is scored 1-3 with 3 indicating most severe derangement. The determination of CP score may range from 5 to 15 and the final score allows to categorize patients in Child–Pugh A (5–6 points), B (7–9 points) and C (10–15 points). The highest is the score the sickest is the patient.</description>
          <population>Baseline Child-Pugh score vs Follow-up</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Child-Pugh score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.11" spread="1.54"/>
                    <measurement group_id="O2" value="10.00" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Child-Pugh score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.11" spread="1.45"/>
                    <measurement group_id="O2" value="11.13" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 1 year Follow-up</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Meld Score From Baseline to 1 Year Follow-up</title>
        <description>Assessment of the efficacy of human fetal liver progenitor cell transplantation on Meld score.
The Model for End-stage Liver Disease (MELD) scoring system aims at stratifying recipients by their disease severity according to a score estimating the 3-month probability of death on the waiting list. The calculation of an individual’s MELD score is based on three objective lab parameters (bilirubin, serum creatinine and prothrombin time expressed as international normalized ratio, INR) and it includes logarithmic transformations and multiplication by several factors. It ranges between 6 and 40. The highest is the score the lower is the patient’s survival.</description>
        <time_frame>Baseline and 1 year Follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
            <description>Cirrhotic patients in waiting list for Liver Transplantation treated with non-purified and non-selected fetal liver stem cells.</description>
          </group>
          <group group_id="O2">
            <title>Control Patients</title>
            <description>Cirrhotic patients in waiting list for Liver Transplantation on standard therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Meld Score From Baseline to 1 Year Follow-up</title>
          <description>Assessment of the efficacy of human fetal liver progenitor cell transplantation on Meld score.
The Model for End-stage Liver Disease (MELD) scoring system aims at stratifying recipients by their disease severity according to a score estimating the 3-month probability of death on the waiting list. The calculation of an individual’s MELD score is based on three objective lab parameters (bilirubin, serum creatinine and prothrombin time expressed as international normalized ratio, INR) and it includes logarithmic transformations and multiplication by several factors. It ranges between 6 and 40. The highest is the score the lower is the patient’s survival.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Meld score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00" spread="2.96"/>
                    <measurement group_id="O2" value="15.31" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Meld score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.67" spread="3.84"/>
                    <measurement group_id="O2" value="19.06" spread="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 1 year Follow-up</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0437</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treated Patients</title>
          <description>Patients with end-stage chronic liver disease in waiting list for liver transplantation treated with non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Patients with end-stage chronic liver disease in waiting list for liver transplantation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Using a single gynecology unit we had only a 22% rate of fetal donation, necessarily limiting the availability of hFLCs. Our strict inclusion criteria limited the pool of potential patients to enroll.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Giada Pietrosi</name_or_title>
      <organization>ISMETT-UPMC</organization>
      <phone>+390912192111</phone>
      <email>gpietrosi@ismett.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

